<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381536</url>
  </required_header>
  <id_info>
    <org_study_id>114243</org_study_id>
    <nct_id>NCT01381536</nct_id>
  </id_info>
  <brief_title>Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>GSK1550188, A Randomised, Single-blind, Placebo Controlled, Dose Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and&#xD;
      pharmacodynamics (PD) of GSK1550188 in Japanese subjects with Systemic Lupus Erythematosus&#xD;
      (SLE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2010</start_date>
  <completion_date type="Actual">November 27, 2010</completion_date>
  <primary_completion_date type="Actual">November 27, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety, tolerability</measure>
    <time_frame>For 84 days</time_frame>
    <description>Number of subjects with adverse events (AE) as meaasure of safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate pharmacokinetics and pharmacodynamics</measure>
    <time_frame>84days</time_frame>
    <description>Serum concentrations of GSK1550188 and derived PK parameters for phamacokinetics, Immunoglobulins (IgG, IgM and IgA), complement (C3, C4), CH50, autoantibodies (anti-double stranded deoxyribonucleic acid [dsDNA] and anti-nuclear antibody [ANA]), B cell subsets (CD20+, CD20+/27+ memory, CD20+/27-na√Øve, CD20+/69+ activated, CD20+/138+ plasmacytoid, CD19+/27BRIGHT/38BRIGHT SLE subset and CD20-/138+ plasma cells), anti-belimumab antibody, BLyS protein, and Safety of Estrogen in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>GSK1550188 1mg/kg or 10mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one shot IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1550188 1mg/kg or 10mg/kg</intervention_name>
    <description>IV one shot</description>
    <arm_group_label>GSK1550188 1mg/kg or 10mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who gave consent to this study participation and signed into informed consent&#xD;
             form.&#xD;
&#xD;
          -  Subjects who are at least 20 years of age at Screening visit.&#xD;
&#xD;
          -  Have a clinical diagnosis of Systemic Lupus Erythematosus (SLE) according to the&#xD;
             American College of Rheumatology (ACR) classification criteria, with 4 or more of the&#xD;
             11 ACR criteria present, serially or simultaneously during any interval or&#xD;
             observation.&#xD;
&#xD;
          -  Be on either no SLE medication or a stable SLE treatment regimen of any medication&#xD;
             (e.g., low-dose prednisone, NSAIDs; alone or in combination) for a period of at least&#xD;
             2 months prior to the Screening visit.&#xD;
&#xD;
          -  Males and females. A female subject is eligible to enter the study if at least one of&#xD;
             the following conditions apply:&#xD;
&#xD;
          -  Not pregnant or nursing;&#xD;
&#xD;
          -  Of non-childbearing potential (ie, women who had a hysterectomy, are postmenopausal&#xD;
             which is defined as 1 year without menses, have both ovaries surgically removed or&#xD;
             have current documented tubal ligation); or&#xD;
&#xD;
          -  Of childbearing potential (ie, women with functional ovaries and no documented&#xD;
             impairment of oviductal or uterine function that would cause sterility). This category&#xD;
             includes women with oligomenorrhoea [even severe], women who are perimenopausal or&#xD;
             have just begun to menstruate. These women must have a negative serum pregnancy test&#xD;
             at screening, and agree to 1 of the following:&#xD;
&#xD;
          -  Complete abstinence from penile-vaginal intercourse, when this is the female's&#xD;
             preferred and usual lifestyle, from 2 weeks prior to administration of the 1st dose of&#xD;
             investigational product until 8 weeks after the last dose of investigational product;&#xD;
             or&#xD;
&#xD;
          -  Consistent and correct use of 1 of the following acceptable methods of birth control&#xD;
             for 1 month prior to the start of the investigational product and for 8 weeks after&#xD;
             the last dose of investigational product:&#xD;
&#xD;
          -  Implants of etonogestrel or levonorgestrel;&#xD;
&#xD;
          -  Estrogenic vaginal ring&#xD;
&#xD;
          -  Injectable progesterone&#xD;
&#xD;
          -  Any intrauterine device (IUD) or intrauterine system (IUS) with a documented failure&#xD;
             rate of less than 1% per year&#xD;
&#xD;
          -  Oral contraceptives (either combined or progesterone only)&#xD;
&#xD;
          -  Double barrier method with vaginal spermicidal agent: Condom and an occlusive cap&#xD;
             (cervical cap/vault or diaphragm) with a vaginal spermicidal agent&#xD;
             (foam/gel/film/cream/suppository)&#xD;
&#xD;
          -  Percutaneous contraceptive patch&#xD;
&#xD;
          -  The subject is positive test for anti-nuclear antibody (ANA) or anti-dsDNA antibody in&#xD;
             serum&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active lupus nephritis requiring hemodialysis, intravenous cyclophosphamide&#xD;
             (Cytoxan),or high-dose prednisone (&gt;60 mg/day) within 6 months prior to the Screening&#xD;
             visit&#xD;
&#xD;
          -  The subject has severe lupus kidney disease (defined by proteinuria &gt; 6 g/day) within&#xD;
             6 months prior to the Screening visit.&#xD;
&#xD;
          -  Received IVIG or plasmapheresis within 6 months prior to Screening visit&#xD;
&#xD;
          -  Active CNS lupus [including seizures, psychosis, organic brain syndrome,&#xD;
             cerebrovascular accident (CVA), motor neuropathy, vasculitis] requiring medical&#xD;
             intervention within 6 months prior to Screening visit&#xD;
&#xD;
          -  The subject has hypogammaglobulinemia or IgA deficiency (IgA level &lt; 10 mg/dL)&#xD;
&#xD;
          -  History of renal transplant&#xD;
&#xD;
          -  History or clinical evidence of active significant acute or chronic diseases (i.e.,&#xD;
             cardiovascular, pulmonary, untreated hypertension, anemia, gastrointestinal, hepatic,&#xD;
             renal, neurological, cancer, or infectious diseases) which, in the opinion of the&#xD;
             investigator, could confound the results of the study or put the subject at undue risk&#xD;
&#xD;
          -  History of any other medical disease, laboratory abnormalities, or conditions which&#xD;
             would make the subject (in the opinion of the Investigator) unsuitable for the study&#xD;
&#xD;
          -  History of any infection requiring hospitalization or parenteral antibiotics within 4&#xD;
             weeks prior to Screening visit&#xD;
&#xD;
          -  The subject has an abnormality on 12-lead ECG at screening which is clinically&#xD;
             significant in the opinion of the investigator.&#xD;
&#xD;
          -  The subject is currently participating in another clinical study or post-marketing&#xD;
             study in which the subject is or will be exposed to an investigational agent.&#xD;
&#xD;
          -  The subject has received a biologic investigational and non-investigational agent&#xD;
             within 12 months prior to the dosing day.&#xD;
&#xD;
          -  The subject has received a non-biologic investigational agent within 2 months prior to&#xD;
             the dosing day.&#xD;
&#xD;
          -  Have evidence of current drug or alcohol abuse or dependence.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2x upper limit of&#xD;
             normal (ULN); alkaline phosphatase and bilirubin &gt;1.5xULN (isolated bilirubin &gt;1.5ULN&#xD;
             is acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Have a historically positive HIV test or test positive at screening for HIV.&#xD;
&#xD;
          -  History of, or positive test at Screening visit for any of HBsAg, anti-HBcAb or&#xD;
             anti-HCVAb. If only anti-HBcAb result is positive, HBV-DNA test will be performed. If&#xD;
             HBV-DNA results in negative, the patient is eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>982-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Yamada M, Akita M, Nakagawa T, Takahashi N, Endo A, Yoshida P. Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus. J Drug Assess. 2013 Apr 12;2(1):40-8. doi: 10.3109/21556660.2013.792823. eCollection 2013.</citation>
    <PMID>27536436</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti Blys Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114243</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114243</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114243</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114243</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114243</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114243</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

